Product Description
Tremelimumab (Imjudo) is a human monoclonal antibody that targets the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Imjudo blocks the activity of CTLA-4, contributing to T-cell activation, priming the immune response to cancer and fostering cancer cell death. (Sourced from: https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-advanced-liver-cancer.html)
Mechanisms of Action: CTLA4 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Brazil | Croatia | Czech | Denmark | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Latvia | Lithuania | Mexico | Peru | Poland | Portugal | Romania | Slovakia | Spain | Sweden | United Arab Emirates | United States
Approved Indications: Hepatocellular Carcinoma | Oncology Unspecified
Known Adverse Events: Abdominal Pain | Labor Pain | Pain Unspecified | Pruritus | Musculoskeletal Pain | Diarrhea
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Egypt, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 97
Highest Development Phases
Phase 3: Bladder Cancer|Hepatocellular Carcinoma|Muscle Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Renal Cell Carcinoma|Small Cell Lung Cancer|Transitional Cell Carcinoma
Phase 2: Adenocarcinoma|Adenocarcinoma in Situ|Anaplastic Thyroid Carcinoma|Biliary Tract Cancer|Breast Cancer|Carcinoma, Merkel Cell|Cholangiocarcinoma|Colorectal Cancer|Dysgerminoma|Endometrial Cancer|Esophageal Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Kidney Cancer|Liver Cancer|Liver Cirrhosis|Lung Cancer|Lyme Disease|Lymphoma|Medullary Carcinoma|Melanoma|Mesothelioma|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Nose Cancer|Oncology Unspecified|Ovarian Cancer|Pancreatic Cancer|Papillary Carcinoma|Papillary Follicular Carcinoma|Papilloma|Prostate Cancer|Sarcoma|Seminoma|Soft Tissue Cancer|Squamous Cell Carcinoma|T-Cell Cutaneous Lymphoma|Testicular Cancer|Thyroid Cancer|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) | P3 |
Unknown status |
Renal Cell Carcinoma |
2038-01-08 |
|
| Volga | P3 |
Active, not recruiting |
Transitional Cell Carcinoma|Bladder Cancer |
2030-07-28 |
|
| I238 | P2 |
Recruiting |
Oncology Unspecified |
2030-04-30 |
|
| J2477 | P1 |
Not yet recruiting |
Biliary Tract Cancer|Pancreatic Cancer |
2029-01-01 |